IP Library Granted Patent US 7,115,574
Granted Patent B2
US 7,115,574 · App. 10/015,055 · Granted Oct 3, 2006

System and method for support legacy operating system booting in a legacy-free system

Assignee: Zengen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,574
App. No.
10/015,055
Granted
Oct 3, 2006
Kind
B2
Abstract

The invention includes a composition and method of treatment of sinusitis. A preferred embodiment of the invention is a composition for treatment of sinusitis comprising a therapeutically effective amount of one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3) used in combination with a therapeutically effective amount of an antihistamine/decongestant, corticosteroid, fungicide and/or antibiotic. In yet another embodiment of the invention, one or one or more peptides selected from the group of peptides with a C-terminal sequence consisting of KPV (SEQ ID NO:1), HFRWGKPV (SEQ ID NO:2), and SYSMEHFRWGKPV (SEQ ID NO:3), which may or may not be in combination with therapeutically effective amounts of antibiotics, corticosteroids and/or antihistamine/decongestants, are topically or systemically applied to treat sinusitis.

Claims (11)

1. A composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal amino acid sequence KPV selected from the group of peptides consisting of KPV (SEQ ID NO: 1), VKP-Ac-CC-Ac-KPV (SEQ ID NO: 4), HFRWGKPV (SEQ ID NO: 2) and SYSMEHFRWGKPV (SEQ ID NO: 3) in combination with a therapeutically effective amount of a decongestant/antihistamine.

2. The composition of claim 1 wherein said decongest/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chloropheniramine, bromopheniramine, pheniramine and loratidine.

3. The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.

4. The composition of claim 3 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cepodoxime proxetil, clarithromycin, and azithramycin.

5. The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.

6. The composition of claim 5 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, budesponide, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, and triamcinolone.

7. The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.

8. The composition of claim 7 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

9. The composition of claim 1 further comprising a carrier.

10. The composition of claim 9 wherein the concentration of said peptide is at least 10 −12 .

11. The composition of claim 10 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin, maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, and hydroxymethyl cellulose with glycerin.

Assignments (4)
MERGER Recorded Oct 15, 2013
From: MSH PHARMA, INC.
To: MSH BIOPHARMA, INC.
Reel/Frame 031411/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2008
From: LIPTON, JAMES M.
To: MSH PHARMA, INCORPORATED
Reel/Frame 020582/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2008
From: ZENGEN, INC.
To: LIPTON, JAMES M.
Reel/Frame 020617/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2003
From: CATANIA, ANNA P.; LIPTON, JAMES M.
To: ZENGEN, INC.
Reel/Frame 014095/0945 →
Continuity (1)
Related Publication 20030109453A1 · Jun 12, 2003